IRIS
ZAJA, Francesco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.585
AS - Asia 4.920
EU - Europa 3.818
SA - Sud America 1.024
AF - Africa 131
Continente sconosciuto - Info sul continente non disponibili 17
OC - Oceania 7
Totale 24.502
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.406
SG - Singapore 2.188
UA - Ucraina 1.178
CN - Cina 1.137
BR - Brasile 797
DE - Germania 633
HK - Hong Kong 539
FI - Finlandia 445
IT - Italia 401
VN - Vietnam 365
RU - Federazione Russa 287
SE - Svezia 256
FR - Francia 195
IE - Irlanda 190
TR - Turchia 139
IN - India 108
CA - Canada 100
GB - Regno Unito 88
AR - Argentina 83
KR - Corea 63
BD - Bangladesh 60
IQ - Iraq 56
MX - Messico 42
CO - Colombia 40
ZA - Sudafrica 35
ID - Indonesia 34
EC - Ecuador 31
IR - Iran 28
MA - Marocco 28
PK - Pakistan 26
JP - Giappone 25
ES - Italia 23
BE - Belgio 22
PH - Filippine 22
VE - Venezuela 22
SA - Arabia Saudita 21
NL - Olanda 15
UZ - Uzbekistan 15
EU - Europa 14
MY - Malesia 14
PY - Paraguay 13
TN - Tunisia 13
KE - Kenya 11
UY - Uruguay 11
CL - Cile 10
JO - Giordania 10
PE - Perù 10
PL - Polonia 10
AE - Emirati Arabi Uniti 9
AT - Austria 9
CH - Svizzera 8
CZ - Repubblica Ceca 8
DZ - Algeria 8
JM - Giamaica 7
NP - Nepal 7
PS - Palestinian Territory 7
AL - Albania 6
AU - Australia 6
BO - Bolivia 6
DO - Repubblica Dominicana 6
EG - Egitto 6
ET - Etiopia 6
RO - Romania 6
RS - Serbia 6
AZ - Azerbaigian 5
KZ - Kazakistan 5
LT - Lituania 5
NI - Nicaragua 5
BH - Bahrain 4
HN - Honduras 4
LB - Libano 4
SN - Senegal 4
AO - Angola 3
BA - Bosnia-Erzegovina 3
CR - Costa Rica 3
GA - Gabon 3
GE - Georgia 3
GR - Grecia 3
GT - Guatemala 3
IL - Israele 3
KG - Kirghizistan 3
KH - Cambogia 3
LV - Lettonia 3
MD - Moldavia 3
PA - Panama 3
TW - Taiwan 3
XK - ???statistics.table.value.countryCode.XK??? 3
BG - Bulgaria 2
CY - Cipro 2
DK - Danimarca 2
HU - Ungheria 2
LU - Lussemburgo 2
OM - Oman 2
PR - Porto Rico 2
PT - Portogallo 2
TG - Togo 2
TH - Thailandia 2
TZ - Tanzania 2
AN - Antille olandesi 1
BJ - Benin 1
Totale 24.475
Salva come PNG Salva come JPEG
Città #
Fairfield 1.819
Woodbridge 1.736
Houston 1.147
Ashburn 1.030
Ann Arbor 968
Singapore 819
Jacksonville 769
Seattle 715
Wilmington 678
Cambridge 617
Beijing 547
Chandler 543
Hong Kong 536
Dearborn 503
San Jose 468
Boardman 241
Princeton 197
Dublin 191
Lauterbourg 168
Munich 162
Los Angeles 138
Udine 131
Ho Chi Minh City 121
Council Bluffs 113
Izmir 112
Dallas 108
San Diego 94
Santa Clara 85
Helsinki 78
São Paulo 77
Buffalo 76
New York 73
Hanoi 72
Hefei 67
Redondo Beach 59
Seoul 56
Ogden 47
The Dalles 45
Des Moines 44
Nanjing 37
Norwalk 36
Ottawa 35
Turku 29
Kunming 28
Rio de Janeiro 27
Dong Ket 25
Florence 25
Mumbai 24
Orem 23
Tokyo 22
Baghdad 20
Johannesburg 20
Montreal 20
Brussels 19
Guangzhou 19
Atlanta 18
Andover 17
Curitiba 17
Toronto 17
Trieste 17
Saint Petersburg 16
Belo Horizonte 15
Boston 15
Shanghai 15
Haiphong 14
Jinan 14
Mexico City 14
Nuremberg 14
Shenyang 14
Bogotá 13
Da Nang 13
Frankfurt am Main 13
Phoenix 13
Dhaka 12
Falls Church 12
Leawood 12
San Francisco 12
Tashkent 12
Brasília 11
Chennai 11
Lappeenranta 11
Milan 11
Nanchang 11
Poplar 11
Quito 11
San Mateo 11
Stockholm 11
Warsaw 11
Amman 10
Chicago 10
Porto Alegre 10
Ardabil 9
Brooklyn 9
Charlotte 9
Denver 9
Recife 9
Salvador 9
Cape Town 8
Chengdu 8
Fortaleza 8
Totale 16.406
Salva come PNG Salva come JPEG
Nome #
Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation 243
Activity of all-trans-retinoic acid in a case of central nervous system extramedullary relapse of acute promyelocytic leukemia 212
Adjuvant treatment with cyclosporin A increases the toxicity of chemotherapy for remission induction in acute non-lymphocytic leukemia. 207
Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases 201
Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial 197
Decreased function of Fas and variations of the perforin gene in adult patients with primary immune thrombocytopenia 197
The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery 188
Low-dose rituximab in adult patients with primary immune thrombocytopenia. 183
ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. 182
Efficacy and safety of rituximab in type II mixed cryoglobulinemia. 178
Efficacy and safety of rituximab in type II mixed cryoglobulinemia 175
Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers 174
Clonality and phenotype in spleens from patients with primary immune thrombocytopenia. 172
Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response. 172
Impact of hepatitis C virus infection on clinical features, quality of life and survival of patients with lymphoplasmacytoid lymphoma/immunocytoma 169
Management of Hodgkin lymphoma in the era of brentuximab vedotin: real-world data from five European countries 168
Management of immune thrombocytopenia in elderly patients 168
Impact of clinical data on chest radiography sensitivity in detecting pulmonary abnormalities in immunocompromised patients with suspected pneumonia 167
Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection 167
Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia 167
Diagnostic framing of IgM monoclonal gammopathy: Focus on Waldenström macroglobulinemia 165
BCL-2 immunohistochemical evaluation in B-cell chronic lymphocytic leukemia and hairy cell leukemia before treatment with fludarabine and 2-chloro-deoxy-adenosine 165
Fludarabine: an active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma. 163
Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma 162
Acute hepatic failure as onset of progressive sclerodermatous chronic graft-versus-host disease after donor lymphocyte infusion. 162
Granulocyte colony-stimulating factor (G-CSF) allows the delivery of effective doses of CHOP and CVP regimens in non-Hodgkin lymphomas. 161
153) LAPAROSCOPIC SPLENECTOMY FOR MASSIVELY ENLARGED SPLEENS: TECHNICAL ASPECTS AND RESULTS OF 8 CONSECUTIVE CASES 160
Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. 160
Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. 160
Delayed and long-lasting complete response to fludarabine in two patients with B-cell chronic lymphocytic leukemia. 159
Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: analysis of 75 patients. 159
Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results 159
More on false thrombocytopenias: EDTA-dependent pseudothrombocytopenia associated with a congenital platelet release defect. 157
B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. 155
Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi 154
A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi 154
Interim positron emission tomography response-adapted therapy in advanced-stage hodgkin lymphoma: Final results of the phase II part of the HD0801 study 153
The efficacy of lenalidomide combination therapy in heavily pretreated non-Hodgkin lymphoma patients: an Italian observational, multicenter, retrospective study 152
Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia. 152
Bendamustine in chronic lymphocytic leukemia: Outcome according to different clinical and biological prognostic factors in the everyday clinical practice. 151
Incidence and diagnosis of EDTA-dependent pseudothrombocytopenia in a consecutive outpatient population referred for isolated thrombocytopenia. 150
Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura 150
Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial 150
Peripheral T-cell lymphoma unspecified PTCL-U): a new prognostic model from a retrospective multicentric clinical study 148
Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT 148
High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: A retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO 148
Allogeneic stem cell transplantation and novel therapies: is the treatment paradigm for younger patients with chronic lymphocytic leukemia changing? 147
Fludarabine in patients with advanced and/or resistant B-chronic lymphocytic leukemia. 146
Efficacy of selective B cell Blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells 146
CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma 146
Clinical relevance of the dose of cytarabine in the upfront treatment of primary CNS lymphomas with methotrexate-cytarabine combination. 145
Rituximab for the treatment of type II mixed cryoglobulinemia 144
B-cell compartment as the selective target for the treatment of immune thrombocytopenias 142
KERATOCONJUNCTIVITIS TREATMENT WITH AUTOLOGOUS SERUM EYE IN PATIENTS WITH SEVERE CHRONIC GVHD 142
Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials 142
Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia 142
T-cell chimerism and clinical outcome after reduced-intensity conditioning allogeneic stem cell transplantation 141
Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: A phase II clinical trial of the fondazione italiana linfomi 141
Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations 141
The role of Rituximab in the therapy of mixed cryoglobulinemia 140
Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease dissemination 140
Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi. 140
Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia 140
Combined therapy with Fludarabine and cyclophosphamide in relapsed/resistant patients with B-cell chronic lymphocytic leukaemia and non-Hodgkin's lymphomas. 139
Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia 139
MYC protein expression scoring and its impact on the prognosis of aggressive B-cell lymphoma patients 139
CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia 138
Occurrence of multiple myeloma after fludarabine treatment of a chronic lymphocytic leukemia: evidence of a biclonal derivation and clinical response to autologous transplantation 137
Quantitative PCR of bone marrow BCL2/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma 137
Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma Network. 137
Surgical staging in Hodgkin's disease: the role of laparoscopic splenectomy 137
The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells 136
NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation 135
Intensified full-dose induction therapy (HD-MACHOP+radiotherapy) follwed dy consolidation with BAVC regimen and autologous stem cell transplantation as fron-line therapeutic approach for high risk aggressive non Hodgkin lymphoma 134
Nocardiosis with favourable clinical outcome in progressive B-chronic lymphocytic leukaemia 134
Successful treatment and FDG-PET/CT monitoring of HHV-6 encephalitis in a non-neutropenic patient: case report and literature review 134
Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab. 133
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. 133
Brentuximab vedotin in combination with extended field radiotherapy as salvage treatment for primary refractory Hodgkin lymphoma. 133
Molecular prediction of durable remission after first-line fludarabinecyclophosphamide-rituximab in chronic lymphocytic leukemia 133
The role of granulocyte colony-stimulating factor (filgrastim) in maintaining dose intensity during conventional-dose chemotherapy with ABVD in Hodgkin's disease. 132
MATILDE chemotherapy regimen for primary CNS lymphoma: results at a median follow-up of 12 years. 132
Sustained response to low-dose rituximab in idiopathic autoimmune hemolytic anemia. 132
NOTCH1 mutational status in chronic lymphocytic leukaemia: Clinical relevance of subclonal mutations and mutation types 132
Rituximab-responsive CIDP. 132
Sequential intensive treatment with the F-MACHOP regimen (+/- radiotherapy) and autologous stem cell transplantation for primary systemic CD30 (Ki-1)--positive anaplastic large cell lymphoma in adults. 131
A retrospective analysis of 144 patients with aggressive non-Hodgkin's lymphoma: impact of aurtologoaus stem cell transplantation in first remission on autcome 130
Mutational status of IGHV is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia 130
Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies. 129
The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases. 129
Hepatitis C virus infection among cryoglobulinemic and non-cryoglobulinemic B-cell non-Hodgkin’s lymphomas 128
No evidence for B-cell clonality by spectratyping analysis in patients with idiopathic thrombocytopenic purpura undergoing rituximab therapy” 128
New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment? 128
Temozolomide as salvage treatment in primary brain lymphomas 127
MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas 127
Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: an Italian observational multicenter retrospective study in daily clinical practice. 127
Gemcitabine as frontline treatment for cutaneous T-cell lymphoma. Phase II study of 32 patients 127
Indolent B-cell lymphomas associated with HCV infection: clinical and virological features and role of antiviral therapy. 126
A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma. 126
High dose therapy with stem cell rescue in elderly atients with aggressive poor risk lymphomas: a review of 14 cases. 125
Totale 15.055
Salva come PNG Salva come JPEG
Categoria #
all - tutte 91.097
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 91.097
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.580 57 183 71 109 52 78 100 87 15 261 303 264
2022/20231.323 214 72 20 135 141 398 0 91 171 18 34 29
2023/2024381 60 22 10 14 69 46 22 14 65 25 15 19
2024/20253.199 52 252 154 66 120 168 214 204 342 261 466 900
2025/20265.670 378 649 501 523 825 451 689 186 430 518 358 162
2026/202796 96 0 0 0 0 0 0 0 0 0 0 0
Totale 24.958